EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY

Abstract Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited. The histone 3.3(K27M) mutation in ~80% of such tumors offers a unique opportunity for immunotherapy intervention, as it defines a high affin...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 21; no. Supplement_6; p. vi93
Main Authors Gromeier, Matthias, Mosaheb, Mubeen, Dobrikova, Elena, Brown, Michael, Bigner, Darell, Ashley, David
Format Journal Article
LanguageEnglish
Published US Oxford University Press 11.11.2019
Subjects
Online AccessGet full text
ISSN1522-8517
1523-5866
DOI10.1093/neuonc/noz175.382

Cover

Abstract Abstract Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited. The histone 3.3(K27M) mutation in ~80% of such tumors offers a unique opportunity for immunotherapy intervention, as it defines a high affinity, HLA-A2-restricted tumor neoantigen that spontaneously elicits CD8+ T cell responses in DIPG patients. Immunizing against the H3.3(K27M) signature in the clinic has been challenging, as conventional approaches (i.e. peptide-conjugates administered with adjuvants) lack the costimulatory signals known to drive CD8+ effector T cell responses. Therefore, we built on a viral vector approach for engaging innate immune responses to virus infection specifically in antigen presenting cells. Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T cell priming against foreign antigens. Polioviruses can provide a context optimal for generating antigen-specific CD8 T cells, as they have natural tropism for dendritic cells, preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and lack interference with innate or adaptive immunity. However, notorious genetic instability and underlying neuropathogenicity has hampered poliovirus-based vector applications. We devised a strategy based on the polio:rhinovirus chimera PVSRIPO, devoid of viral neuropathogenicity after intracerebral inoculation in human subjects, for stable expression of exogenous antigens. PVSRIPO vectors infect, activate, and induce epitope presentation in DCs in vitro; recruit and activate DCs with Th1-dominant cytokine profiles at the injection site in vivo. They efficiently prime tumor antigen-specific CD8 T cells in vivo, induce CD8 T cell migration to the tumor site, delay tumor growth and enhance survival in syngeneic rodent tumor models. We are preparing a prototype PVSRIPO-derived vector delivering the H3.3(K27M) signature for clinical investigation.
AbstractList Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited. The histone 3.3(K27M) mutation in ~80% of such tumors offers a unique opportunity for immunotherapy intervention, as it defines a high affinity, HLA-A2-restricted tumor neoantigen that spontaneously elicits CD8+ T cell responses in DIPG patients. Immunizing against the H3.3(K27M) signature in the clinic has been challenging, as conventional approaches (i.e. peptide-conjugates administered with adjuvants) lack the costimulatory signals known to drive CD8+ effector T cell responses. Therefore, we built on a viral vector approach for engaging innate immune responses to virus infection specifically in antigen presenting cells. Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T cell priming against foreign antigens. Polioviruses can provide a context optimal for generating antigen-specific CD8 T cells, as they have natural tropism for dendritic cells, preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and lack interference with innate or adaptive immunity. However, notorious genetic instability and underlying neuropathogenicity has hampered poliovirus-based vector applications. We devised a strategy based on the polio:rhinovirus chimera PVSRIPO, devoid of viral neuropathogenicity after intracerebral inoculation in human subjects, for stable expression of exogenous antigens. PVSRIPO vectors infect, activate, and induce epitope presentation in DCs in vitro; recruit and activate DCs with Th1-dominant cytokine profiles at the injection site in vivo. They efficiently prime tumor antigen-specific CD8 T cells in vivo, induce CD8 T cell migration to the tumor site, delay tumor growth and enhance survival in syngeneic rodent tumor models. We are preparing a prototype PVSRIPO-derived vector delivering the H3.3(K27M) signature for clinical investigation.
Abstract Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited. The histone 3.3(K27M) mutation in ~80% of such tumors offers a unique opportunity for immunotherapy intervention, as it defines a high affinity, HLA-A2-restricted tumor neoantigen that spontaneously elicits CD8+ T cell responses in DIPG patients. Immunizing against the H3.3(K27M) signature in the clinic has been challenging, as conventional approaches (i.e. peptide-conjugates administered with adjuvants) lack the costimulatory signals known to drive CD8+ effector T cell responses. Therefore, we built on a viral vector approach for engaging innate immune responses to virus infection specifically in antigen presenting cells. Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T cell priming against foreign antigens. Polioviruses can provide a context optimal for generating antigen-specific CD8 T cells, as they have natural tropism for dendritic cells, preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and lack interference with innate or adaptive immunity. However, notorious genetic instability and underlying neuropathogenicity has hampered poliovirus-based vector applications. We devised a strategy based on the polio:rhinovirus chimera PVSRIPO, devoid of viral neuropathogenicity after intracerebral inoculation in human subjects, for stable expression of exogenous antigens. PVSRIPO vectors infect, activate, and induce epitope presentation in DCs in vitro; recruit and activate DCs with Th1-dominant cytokine profiles at the injection site in vivo. They efficiently prime tumor antigen-specific CD8 T cells in vivo, induce CD8 T cell migration to the tumor site, delay tumor growth and enhance survival in syngeneic rodent tumor models. We are preparing a prototype PVSRIPO-derived vector delivering the H3.3(K27M) signature for clinical investigation.
Author Gromeier, Matthias
Brown, Michael
Bigner, Darell
Ashley, David
Mosaheb, Mubeen
Dobrikova, Elena
AuthorAffiliation Duke University Medical Center , Durham, NC, USA
AuthorAffiliation_xml – name: Duke University Medical Center , Durham, NC, USA
Author_xml – sequence: 1
  givenname: Matthias
  surname: Gromeier
  fullname: Gromeier, Matthias
  organization: Duke University Medical Center, Durham, NC, USA
– sequence: 2
  givenname: Mubeen
  surname: Mosaheb
  fullname: Mosaheb, Mubeen
  organization: Duke University Medical Center, Durham, NC, USA
– sequence: 3
  givenname: Elena
  surname: Dobrikova
  fullname: Dobrikova, Elena
  organization: Duke University Medical Center, Durham, NC, USA
– sequence: 4
  givenname: Michael
  surname: Brown
  fullname: Brown, Michael
  organization: Duke University Medical Center, Durham, NC, USA
– sequence: 5
  givenname: Darell
  surname: Bigner
  fullname: Bigner, Darell
  organization: Duke University Medical Center, Durham, NC, USA
– sequence: 6
  givenname: David
  surname: Ashley
  fullname: Ashley, David
  organization: Duke University Medical Center, Durham, NC, USA
BookMark eNqNkMFOg0AQhjemJrbVB_C2DyAts8vuwsWkVtqSQCGUNva0YWHRmhYasCb69FIxJt68zEzyz_8dvgHqlVWpEboFcwSmQ8elPlVlNi6rTxBsRG1ygfrACDWYzXnv-yaGzUBcoUHTvJomAcahjwL3KVkYDEZ47i7dxJtOfH-LV8nkwXdxFPpeuPHi9Qpv3GkSxjjyJ8ksjAPcDvzoRXPsBcF6GSYLN55E22t0WaT7Rt_87CFaz9xkujD8cH5GGxkIQQwnLQi1iOZKK3BoXiiqLWXTNiXCZsLkPFWQK6EcZVsFYZBS5eS5lXHOC-B0iO477vGkDjrPdPlWp3t5rHeHtP6QVbqTf5Ny9yKfq3fJbUvYFrQA6ABZXTVNrYvfLpjyLFR2QmUnVLZC285d16lOx3-8fwFut3el
ContentType Journal Article
Copyright The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019
Copyright_xml – notice: The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019
DBID AAYXX
CITATION
5PM
DOI 10.1093/neuonc/noz175.382
DatabaseName CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
DatabaseTitleList CrossRef


DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Abstracts from the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 22 – 24, 2019 Phoenix, Arizona
EISSN 1523-5866
EndPage vi93
ExternalDocumentID PMC6847841
10_1093_neuonc_noz175_382
10.1093/neuonc/noz175.382
GroupedDBID ---
.2P
.I3
.XZ
.ZR
0R~
123
18M
2WC
36B
4.4
48X
53G
5VS
5WD
70D
AABZA
AACZT
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
ABEUO
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AOIJS
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EMB
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HYE
HZ~
IOX
J21
KBUDW
KOP
KQ8
KSI
KSN
MHKGH
N9A
NGC
NOMLY
NOYVH
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
Q1.
Q5Y
RD5
RHF
ROX
RPM
RUSNO
RW1
RXO
SV3
TEORI
TJX
TR2
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
~91
AAYXX
ABDFA
ABEJV
ABGNP
ABPQP
ABVGC
ADNBA
AEMQT
AHGBF
AHMMS
AJBYB
AJNCP
ALXQX
CITATION
JXSIZ
5PM
ID FETCH-LOGICAL-c1772-9af2342e6beb193dfb3e4b83c1727857066ab1db7b9b84f251a3b9dd4c666f163
ISSN 1522-8517
IngestDate Tue Sep 30 16:43:33 EDT 2025
Wed Oct 01 04:08:56 EDT 2025
Wed Aug 28 03:18:50 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_6
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1772-9af2342e6beb193dfb3e4b83c1727857066ab1db7b9b84f251a3b9dd4c666f163
OpenAccessLink https://academic.oup.com/neuro-oncology/article-pdf/21/Supplement_6/vi93/30632104/noz175.382.pdf
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6847841
crossref_primary_10_1093_neuonc_noz175_382
oup_primary_10_1093_neuonc_noz175_382
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20191111
PublicationDateYYYYMMDD 2019-11-11
PublicationDate_xml – month: 11
  year: 2019
  text: 20191111
  day: 11
PublicationDecade 2010
PublicationPlace US
PublicationPlace_xml – name: US
PublicationTitle Neuro-oncology (Charlottesville, Va.)
PublicationYear 2019
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0021561
Score 2.2600546
Snippet Abstract Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited....
Options for the immunotherapy of diffuse intrinsic pontine glioma (DIPG), due to its anatomical location and inherent therapy resistance, are limited. The...
SourceID pubmedcentral
crossref
oup
SourceType Open Access Repository
Index Database
Publisher
StartPage vi93
SubjectTerms Experimental Therapeutics
Title EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY
URI https://pubmed.ncbi.nlm.nih.gov/PMC6847841
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1523-5866
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0021561
  issn: 1522-8517
  databaseCode: KQ8
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1523-5866
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0021561
  issn: 1522-8517
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1523-5866
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0021561
  issn: 1522-8517
  databaseCode: GX1
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1523-5866
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0021561
  issn: 1522-8517
  databaseCode: RPM
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviKsYN_kBXojSLXFufixbWIuatSrpVJ4in8TRIqQEjbYP-0f8S47jpE0YSBsvVuq2R4nPF_s79rkQ8p7lqcpSJk0HeIoGiiNMwTIw3dxlggcsBakCnKNzb7x0vqzc1WDwq-O1tFnDML3-a1zJ_2gV-1CvKkr2DprdCcUOvEb9YosaxvZWOg5X8dh0raGhHNBildlg-g053ujTNDTms-lkdjFZLL8aF-FJPFsY8-koRpsvMrAxTifzM2MSRcvzWTwOF6N5j6bWKTvMqkx1hiZ10quO5as1EtOtih6s3WPFsLOPcKbyHhQaAHUR8ULs6HpU_RSXsj75iTYg99FnpxVcFd-rrdAeZrK8uT3Q9etvdicsrsL0mtmzmVDR2EVWpxdV2fYx0w10tZV2FratDtrqiqb19mjSnV23ha6m2KzU7ccbq4DOkFXKDY6TuqiukSQNma5y1M-5_cdauPNQ1GfzLNFCEi0iQRH3yH3b9zy73RhqbHs0g3Vq3uZx2wN0zo60iKP9XfQokA6r7DvkdhhO_Jg8akwTOtI4e0IGsnxKHkSN88UzErVwox24UQ03uocb1XCjLdwoNlTBjfbg9pwsP4fxydhsqnGYqYUmmMlFbjPHlh7g8s5ZlgOTDuDbrCiwKpPgeQKsDHzgEDg58mbBgGeZk6KFnCPtf0EOyqqULwk9ZgyxItw04KnjZwBwDLlwXV_gwNpcHpKP7QAlP3TSleSfCjkkH3AIb_M7vzfIu3-oBOv9b8risk607iF1Cxzr1V1u5zV5uH8P3pCD9dVGvkXeuoZ3NWJ-Azrpkew
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EXTH-51.+GENETICALLY+STABLE+POLIOVIRUS+VECTOR+PLATFORM+FOR+DIPG+IMMUNOTHERAPY&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Gromeier%2C+Matthias&rft.au=Mosaheb%2C+Mubeen&rft.au=Dobrikova%2C+Elena&rft.au=Brown%2C+Michael&rft.date=2019-11-11&rft.issn=1522-8517&rft.eissn=1523-5866&rft.volume=21&rft.issue=Supplement_6&rft.spage=vi93&rft.epage=vi93&rft_id=info:doi/10.1093%2Fneuonc%2Fnoz175.382&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_neuonc_noz175_382
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon